2024 USCAST Virtual Public Meeting
We are pleased to report that we had nearly 100 attendees join our virtual meeting on December 5, 2024, to hear about recent updates from USCAST and the 2024-25 in vitro susceptibility test interpretive criteria (STIC, also known as susceptibility breakpoints) recommendations. STIC were reviewed for ceftriaxone and azithromycin against Neisseria gonorrhoeae, the oral cephalosporins, cephalexin, cefuroxime, and cefpodoxime, against E. coli and S. aureus, and trimethoprim-sulfamethoxazole against Enterobacterales for uncomplicated urinary tract infections. Links to all slide presentations and Zoom videos from these presentations can be found below. The USCAST STIC recommendations based on these presentations are now open for public comment for the next 60 days. This open public comment period will end on February 15, 2025.
USCAST encourages all interested parties to review the presentations and to provide feedback on the content and recommendations for the topics presented via the USCAST website. Feedback that is received will be reviewed and considered prior to the finalization of STIC recommendations. USCAST values the input from participants of the virtual meeting, our community, and the public. Please submit public comments here. We look forward to hearing from you!
Ceftriaxone and Azithromycin STIC against N. gonorrhoeae
Sujata N. Bhavnani, Pharm. D.
Vice Chair, USCAST
Oral cephalosporin STIC against S. aureus and E. coli
David Andes, MD
Executive Committee Member, USCAST
Trimethoprim-Sulfamethoxazole STIC against Enterobacterales Uncomplicated Urinary Tract Infections
Jason M. Pogue, Pharm. D.
Chairman, USCAST
In 2023, USCAST developed in vitro susceptibility test interpretive criteria (STIC, also known as susceptibility breakpoints) for the following clinical scenarios: 1) piperacillin/tazobactam against Enterobacterales and Pseudomonas aeruginosa; 2) amikacin, ceftazidime, ciprofloxacin, and minocycline against Acinetobacter baumannii; and 3) aminoglycosides against Enterobacterales and P. aeruginosa. Recordings from our virtual meeting can be found here and our updated breakpoints table can be found here.